Join to view full profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Fax+1 650-498-5840
Dr. Neal is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2004 - 2007
Northwestern University The Feinberg School of MedicineClass of 2004
Certifications & Licensure
CA State Medical License 2010 - 2027
MA State Medical License 2006 - 2011
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
Publications & Presentations
PubMed
- SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.Jamie Chaft, Jay M Lee, Suresh Senan, Joel W Neal, Ernest Nadal
Future Oncology. 2026-10-01 - 5 citationsEnsemble learning of pathology foundation models for precision oncology.Xiangde Luo, Xiyue Wang, Feyisope Eweje, Xiaoming Zhang, Juan Luis Gomez Marti
Cancer Cell. 2026-09-10 - 2 citationsCrizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American Colle...David E Gerber, Yating Wang, Corey J Langer, Onkar V Khullar, David E Kozono
The Lancet. Respiratory Medicine. 2026-08-25
Lectures
- Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Other
- Personalized, genotype-directed therapy for advanced non-small cell lung cancerNeal JW, Sequist LV
http://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-
UpToDate, Wolters Kluwer Health - 2013-02-25
Press Mentions
How Stanford Made Trial Referrals Part of the Oncology WorkflowNovember 4th, 2025- Enhertu Marks First Targeted Therapy for HER2-Mutant Lung CancerSeptember 13th, 2022
Exelixis Announces Results from COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Multiple Advanced Solid Tumor TypesMay 13th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: